Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Acta Neurologica Scandinavica, Supplement

Volumn 107, Issue 179, 2003, Pages 47-51

  Andreasen, Niels ^a   Vanmechelen, Eugeen ^b   Vanderstichele, Hugo ^b   Davidsson, Pia ^c   Blennow, Kaj ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INNOGENETICS   (Belgium)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; B amyloid (A ); Biochemical markers; Cerebrospinal fluid (CSF); Mild cognitive impairment (MCI); Phosphorylated tau (P tau); Total tau (T tau)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOCHEMICAL MARKER; GAMMA SECRETASE; PHOSPHOPROTEIN TAU; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHOSPHORYLATION; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; CEREBROSPINAL FLUID LEVEL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LIKELIHOOD FUNCTIONS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 0037244487     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. MCKHANN G, DRACHMAN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
2. COLEMAN PD, FLOOD DG. Neuron numbers and dendrite extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987;8:521-45.
3. DAVIDSSON P, BLENNOW K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatrics 1998;10:11-23.
4. GOEDERT M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. TINS 1993;16:460-5.
5. MASTERS CL, SIMMS G, WEINMAN NA, MULTHAUP G, MCDONALD BL, BEYREUTHER K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci 1985, 82.
6. GRUNDKE-IQBAL I, IQBAL K, TUNG YC, QUINLAN M, WISNIEWSKI HM, BINDER LI. Abnormal phosphorylation of the microtubule-associated protein θ (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83:4913-7.
7. HULSTAERT F, BLENNOW K, IVANOIU A et al. Improved discrimination of Alzheimer's disease patients from other subject groups using the combined measure of [β-amyloid (1-42) and tau in CSF; a multicenter study. Neurology, 52 1999 1555-62.
8. ANDREASEN N, MINTHON L, CLARBERG A et al. Sensitivity, specificity and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999;53:1488-94.
9. ANDREASEN N, MINTHON L, DAVIDSSON P et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch Neurol 2001; 58:373-379.
10. BLENNOW K, WALLIN A, ÅGREN H, SPENGER C, SIEGFRIED J, VANMECHELEN E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26: 231-45.
11. ISHIGURO K, OHNO H, ARAI H et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-4.
12. KOHNKEN R, BUERGER K, ZINKOWSKI R et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000;287: 187-90.
13. VANMECHELEN E, VANDERSTICHELE H, DAVlDSSON P et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
14. RIEMENSCHNEIDER M, BUCH K, SCHMOLKE M, KURZ A, GUDER WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996;212:209-11
15. GALASKO D, CLARK C, CHANG L et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632-5.
16. GALASKO D, CLARK C, CHANG L et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-45.
17. KURZ A, RIEMENSCHNEIDER M, BUCH K et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:372-7.
18. (1-42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 1999;56:673-80.
19. RIEMENSCHNEIDER M, SCHMOLKE M, LAUTENSCHLAGER N et al. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipo protein E genotype and cognitive decline. Neurosci Lett 2000;284:85-8.
20. FOLSTEIN M, FOLSTEIN S, MCHUGH P. 'Mini-Mental State' a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
21. ARAI H, NAKAGAWA T, KOSAKA Y et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer's Res 1997;3:211-3.
22. ANDREASEN N, MINTHON L, VANMECHELEN E et al. CSF-tau and CSF-Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.
23. ARAI H, ISHIGURO K, OHNO H et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000;166:201-3.
24. BUERGER K, TEIPEL SJ, ZINKOWSKI R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-9.
25. ANDREASEN N, BLENNOW K, SJÖDIN C, SVÄRDSUDD K. Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Piteå Dementia Project. Neuroepidemiology 1999;18:144-155.
26. PETERSEN RC, SMITH GE, IVNIK RJ et al. Apolipoprotein E. status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274-8.
27. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
28. PETERSEN RC, SMITH GE, WARING SC, IVNIK RJ, TANGALOS EG, KOKMEN E. Mild cognitive impairment, clinical characterization and outcome. Arch Neurol 1999;56: 303-8.
29. INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY (IFCC). Approved recommendation on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987;170:13-32.